Drug developers' recent interest in treating bronchiectasis holds potential to improve outcomes

When it comes to lung diseases, asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis might come to mind.

One that may be less familiar is bronchiectasis, however, just over half a million people in the USA will be living with this long-term disease by 2031, according to GlobalData. The bronchiectasis market in 2021 was worth just around $408 million.

Like cystic fibrosis and asthma, there is no cure for bronchiectasis, however, unlike its peers, bronchiectasis has seen a severe lack of investment - and there is a distinct lack of disease-modifying drugs available to patients. However, GlobalData believes this is set to change.